Roche (ROG.SW)

Executive Summary

Roche is a global leader in pharmaceuticals and diagnostics, with a strong portfolio spanning oncology, immunology, ophthalmology, and neurology. Its innovative medicines, including Tecentriq, Hemlibra, and Vabysmo, have driven consistent revenue growth, while the diagnostics division provides a resilient stream of recurring earnings. Recent strategic moves, such as the acquisition of Spark Therapeutics and partnerships in personalized healthcare, reinforce Roche's commitment to precision medicine. Despite patent cliffs on mature products like Herceptin and Avastin, new launches and label expansions are expected to offset headwinds. The company's deep pipeline, with over 60 Phase III trials, targets high-value indications, including solid tumors and rare diseases. With a strong balance sheet and a proven track record in R&D execution, Roche is well-positioned for sustainable long-term growth.

Upcoming Catalysts (preview)

• H2 2026Tiragolumab + Tecentriq Phase 3 results in 1L NSCLC (SKYSCRAPER-01)60% success
• H1 2026FDA decision on crovalimab for paroxysmal nocturnal hemoglobinuria (PNH)80% success
• Q4 2026Phase 3 data for inavolisib (GDC-0077) in PIK3CA-mutated HR+ breast cancer (INAVO121)65% success